BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35100894)

  • 21. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I; van Leerdam ME
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1418-1425. PubMed ID: 32777553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 26. One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening: a cross-sectional study in China.
    Wang L; Chen H; Zhu Y; Lu M; Wang Y; Chen X; Ma W; Du L; Chen W
    BMJ Open; 2022 May; 12(5):e059754. PubMed ID: 35589365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic.
    Kortlever TL; de Jonge L; Wisse PHA; Seriese I; Otto-Terlouw P; van Leerdam ME; Spaander MCW; Dekker E; Lansdorp-Vogelaar I
    Prev Med; 2021 Oct; 151():106643. PubMed ID: 34217421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of COVID-19 on national program of colorectal cancer screening in Tehran, Iran: a multicenter study.
    Sadeghi A; Asadzadeh Aghdaei H; Khalafi MA; Nazemalhosseini-Mojarad E; Ketabi Moghadam P; Sohrabi MR
    BMC Cancer; 2023 Jul; 23(1):627. PubMed ID: 37407931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of the faecal immunochemical test during the COVID-19 pandemic to triage urgent colorectal cancer referrals.
    Kamel F; Zulfiqar S; Penfold W; Weatherell S; Madani R; Nisar P; Bearn P
    Colorectal Dis; 2022 Jun; 24(6):727-736. PubMed ID: 35297169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the COVID-19 Pandemic on Colorectal Cancer Screening: a Systematic Review.
    Mazidimoradi A; Tiznobaik A; Salehiniya H
    J Gastrointest Cancer; 2022 Sep; 53(3):730-744. PubMed ID: 34406626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia.
    Naber SK; Almadi MA; Guyatt G; Xie F; Lansdorp-Vogelaar I
    Saudi J Gastroenterol; 2021; 27(4):208-216. PubMed ID: 33835054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: A community-based cohort study.
    Pin-Vieito N; García Nimo L; Bujanda L; Román Alonso B; Gutierrez-Stampa MÁ; Aguilar-Gama V; Portillo I; Cubiella J
    United European Gastroenterol J; 2021 Mar; 9(2):256-267. PubMed ID: 32778002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region.
    Chiu HM; Su CW; Hsu WF; Jen GH; Hsu CY; Chen SL; Chen HH
    Prev Med; 2021 Oct; 151():106622. PubMed ID: 34044024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.
    Thomsen MK; Pedersen L; Erichsen R; Lash TL; Sørensen HT; Mikkelsen EM
    Br J Cancer; 2022 May; 126(8):1229-1235. PubMed ID: 35058592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
    Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
    J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.